Skip to main content

Articles

Page 6 of 60

  1. Diabetes mellitus (DM) is associated with thrombogenicity, clinically manifested with atherothrombotic events after percutaneous cutaneous intervention (PCI). This study aimed to investigate association betwee...

    Authors: Ki-Hyun Jeon, Young-Hoon Jeong, In-Ho Chae, Byeong-Keuk Kim, Hyung Joon Joo, Kiyuk Chang, Yongwhi Park, Young Bin Song, Sung Gyun Ahn, Sang Yeub Lee, Jung Rae Cho, Ae-Young Her, Hyo-Soo Kim, Moo Hyun Kim, Do-Sun Lim, Eun-Seok Shin…
    Citation: Cardiovascular Diabetology 2023 22:245
  2. Insulin resistance (IR) is a major metabolic disorder observed in heart failure (HF) and is tightly associated with patients’ poor prognosis. The triglyceride-glucose index (TyG) has been proposed as a surroga...

    Authors: Amirmohammad Khalaji, Amir Hossein Behnoush, Shaghayegh Khanmohammadi, Kimiya Ghanbari Mardasi, Sourena Sharifkashani, Amirhossein Sahebkar, Caterina Vinciguerra and Alessandro Cannavo
    Citation: Cardiovascular Diabetology 2023 22:244
  3. Endogenous estrogen is cardio-protective in healthy premenopausal women. Despite this favorable action of estrogen, animal models depict a detrimental effect of estradiol on vascular function in the presence o...

    Authors: Abigayle B. Simon, Cassandra C. Derella, Marsha Blackburn, Jeffrey Thomas, Lawrence C. Layman, Matthew S. Nicholson, Jennifer Waller, Ahmed Elmarakby, Karim M. Saad and Ryan A. Harris
    Citation: Cardiovascular Diabetology 2023 22:243
  4. To assess how inaccurately the body mass index (BMI) is used to diagnose obesity compared to body fat percentage (BF%) measurement and to compare the cardiometabolic risk in children and adolescents with or wi...

    Authors: J. Karina Zapata, M. Cristina Azcona-Sanjulian, Victoria Catalán, Beatriz Ramírez, Camilo Silva, Amaia Rodríguez, Javier Escalada, Gema Frühbeck and Javier Gómez-Ambrosi
    Citation: Cardiovascular Diabetology 2023 22:240
  5. High triglyceride-glucose index (TyG) is a major risk factor for heart failure, but the long-term effect of high TyG index on the risk of developing heart failure remains unclear. Therefore, we aimed to determ...

    Authors: Huancong Zheng, Guanzhi Chen, Kuangyi Wu, Weiqiang Wu, Zegui Huang, Xianxuan Wang, Zekai Chen, Zefeng Cai, Zhiwei Cai, Yulong Lan, Shouling Wu and Youren Chen
    Citation: Cardiovascular Diabetology 2023 22:239
  6. The triglyceride-glucose (TyG) index is a reliable surrogate marker of insulin resistance (IR). However, whether the TyG index has prognostic value in patients with moderate to severe aortic stenosis (AS) rema...

    Authors: Rihua Huang, Xinghao Xu, Chaoguang Xu, Shaozhao Zhang, Zhenyu Xiong, Menghui Liu, Yiquan Huang, Han Wen, Yue Guo, Xinxue Liao and Xiaodong Zhuang
    Citation: Cardiovascular Diabetology 2023 22:238
  7. Diabetes mellitus is a metabolic disease characterized by long-term hyperglycaemia, which leads to microangiopathy and macroangiopathy and ultimately increases the mortality of diabetic patients. Endothelial d...

    Authors: Ying An, Bu-tuo Xu, Sheng-rong Wan, Xiu-mei Ma, Yang Long, Yong Xu and Zong-zhe Jiang
    Citation: Cardiovascular Diabetology 2023 22:237
  8. The presence of type 1 diabetes mellitus (T1DM) has been demonstrated to pose an increased risk for developing cardiovascular diseases (CVDs). However, the causal relationships between T1DM and CVDs remain unc...

    Authors: Zirui Liu, Haocheng Wang, Zhengkai Yang, Yu Lu and Cao Zou
    Citation: Cardiovascular Diabetology 2023 22:236
  9. Randomized controlled trials (RCTs) reported contrasting results about reverse left ventricular remodeling (LVR) after sodium-glucose co-transporter-2 inhibitors (SGLT2i) therapy in patients with heart failure...

    Authors: Erberto Carluccio, Paolo Biagioli, Gianpaolo Reboldi, Anna Mengoni, Rosanna Lauciello, Cinzia Zuchi, Sandra D’Addario, Giuliana Bardelli and Giuseppe Ambrosio
    Citation: Cardiovascular Diabetology 2023 22:235
  10. Microvascular dysfunction plays a crucial role in complications of type 2 diabetes and might contribute to heart failure with preserved ejection fraction (HFpEF), a disease that disproportionally affects women...

    Authors: Elisa Dal Canto, L. van Deursen, A. G. Hoek, P. J. M. Elders, H. M. den Ruijter, J. van der Velden, V. van Empel, E. H. Serné, E. C. Eringa and J. W.J. Beulens
    Citation: Cardiovascular Diabetology 2023 22:234
  11. Studies that have reported lower risk for cardiovascular outcomes in users of Sodium–Glucose Cotransporter-2 Inhibitors (SGLT-2i) are limited by residual cofounding and lack of information on prior cardiovascu...

    Authors: Dorte Vistisen, Bendix Carstensen, Patorno Elisabetta, Stefanie Lanzinger, Elise Chia-Hui Tan, Daisuke Yabe, Dae Jung Kim, Wayne H.-H. Sheu, Cheli Melzer-Cohen, Reinhard W. Holl, Júlio Núñez, Kyoung Hwa Ha, Sigrun Halvorsen, Gisle Langslet, Avraham Karasik, Thomas Nyström…
    Citation: Cardiovascular Diabetology 2023 22:233
  12. Insulin resistance (IR) can be effectively assessed using the dependable surrogate biomarker triglyceride-glucose (TyG) index. In various critical care contexts, like contrast-induced acute kidney injury (AKI)...

    Authors: Zewen Yang, Hongxia Gong, Fuqiang Kan and Ningning Ji
    Citation: Cardiovascular Diabetology 2023 22:232
  13. Adipokines are hormones secreted from adipose tissue and are associated with cardiometabolic diseases (CMD). Functional differences between adipokines (leptin, adiponectin, and resistin) are known, but inconsi...

    Authors: Daeeun Kim, Aylin Memili, Hung-Hsin Chen, Heather M. Highland, Hannah G. Polikowsky, Mohammad Yaser Anwar, Susan T. Laing, Miryoung Lee, Joseph B. McCormick, Susan P. Fisher-Hoch, Jennifer E. Below, Kari E. North and Absalon D. Gutierrez
    Citation: Cardiovascular Diabetology 2023 22:231
  14. The triglyceride-glucose (TyG) index has been evaluated as a reliable surrogate for insulin resistance (IR) and has been proven to be a predictor of poor outcomes in patients with cardiovascular diseases. Howe...

    Authors: Zhenguo Wu, Lin Xie, Dachuan Guo, Sha Chen, Xiaoyu Liu, Xiangfei Sun, Juan Wang, Yerui Zhang, Li Liu, Huiliang Cui, Dejin Zang and Jianmin Yang
    Citation: Cardiovascular Diabetology 2023 22:230
  15. Today, diabetes mellitus (DM) has become a worldwide concern. DM is a major risk factor for the development of cardiovascular diseases (CVD). Eligible patients with CVD are treated invasively by percutaneous c...

    Authors: Hong Wang, Quannan Zu, Hairong Tang, Ming Lu, Rongfa Chen and Zhiren Yang
    Citation: Cardiovascular Diabetology 2023 22:228
  16. Outcomes of diabetes screening in contemporary, multi-ethnic populations are unknown. We examined the association of prior outpatient diabetes screening with the risks of cardiovascular events and mortality in...

    Authors: Calvin Ke, Anna Chu, Baiju R. Shah, Sheldon Tobe, Karen Tu, Jiming Fang, Haris Vaid, Peter Liu, Aishah Cader and Douglas S. Lee
    Citation: Cardiovascular Diabetology 2023 22:227
  17. The global prevalence of metabolic syndrome and its association with increased morbidity and mortality has been rigorously studied. However, the true prevalence of “metabolic health”, i.e. individuals without ...

    Authors: Hadas Ben-Assayag, Rafael Y. Brzezinski, Shlomo Berliner, David Zeltser, Itzhak Shapira, Ori Rogowski, Sharon Toker, Roy Eldor and Shani Shenhar-Tsarfaty
    Citation: Cardiovascular Diabetology 2023 22:226
  18. Estimated glucose disposal rate (eGDR), a simple and noninvasive measure of insulin resistance, has been proven to be an independent risk factor for first-time stroke and all-cause mortality. In this study, we...

    Authors: Zhengzhao Lu, Yunyun Xiong, Xueyan Feng, Kaixuan Yang, Hongqiu Gu, Xingquan Zhao, Xia Meng and Yongjun Wang
    Citation: Cardiovascular Diabetology 2023 22:225
  19. Diabetes and hyperlipidaemia are both risk factors for coronary artery disease, and both are associated with a high triglyceride-glucose index (TyG index). The TyG index has been presented as a marker of insul...

    Authors: Jiao Li, Zixian Dong, Hao Wu, Yue Liu, Yafang Chen, Si Li, Yufan Zhang, Xin Qi and Liping Wei
    Citation: Cardiovascular Diabetology 2023 22:224
  20. High-sensitivity C-reaction protein (hsCRP), a biomarker of residual inflammatory risk, has been demonstrated with poor cardiovascular outcomes. We aimed to investigate the prognostic value of hsCRP in patient...

    Authors: Le Li, Shangyu Liu, Zhuxin Zhang, Likun Zhou, Zhenhao Zhang, Yulong Xiong, Zhao Hu and Yan Yao
    Citation: Cardiovascular Diabetology 2023 22:223
  21. Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality, being twofold to fourfold more common in patients with type 2 diabetes mellitus (T2DM) than in individuals withou...

    Authors: Massimiliano Ruscica, Chiara Macchi, Angelica Giuliani, Alessandra Stefania Rizzuto, Deborah Ramini, Matilde Sbriscia, Stefano Carugo, Anna Rita Bonfigli, Alberto Corsini, Fabiola Olivieri and Jacopo Sabbatinelli
    Citation: Cardiovascular Diabetology 2023 22:222
  22. Early postoperative glycemic variability is associated with worse outcome after cardiac surgery, but the underlying mechanisms remain unknown. This study aimed to describe the relationship between postoperativ...

    Authors: Etienne Chazal, Lucas Morin, Sidney Chocron, Philippe Lassalle, Sebastien Pili-Floury, Lucie Salomon du Mont, David Ferreira, Emmanuel Samain, Andrea Perrotti and Guillaume Besch
    Citation: Cardiovascular Diabetology 2023 22:221
  23. Semaglutide is a glucose-lowering treatment for type 2 diabetes (T2D) with demonstrated cardiovascular benefits; semaglutide may also have kidney-protective effects. This post hoc analysis investigated the associ...

    Authors: Peter Rossing, Stephen C. Bain, Heidrun Bosch-Traberg, Ekaterina Sokareva, Hiddo J. L. Heerspink, Søren Rasmussen and Linda G. Mellbin
    Citation: Cardiovascular Diabetology 2023 22:220
  24. Clinical observations suggest a complex relationship between obesity and coronary artery disease (CAD). This study aimed to characterize the intermediate metabolism phenotypes among obese patients with CAD and...

    Authors: Chong-Yu Zhang, Ru-Qin Xu, Xiao-Qiao Wang, Lin-Feng Sun, Pei Mo, Ren-Jie Cai, Xiao-Zhen Lin, Cheng-Feng Luo, Wen-Chao Ou, Lie-Jing Lu, Yun Zhong and Jia-Yuan Chen
    Citation: Cardiovascular Diabetology 2023 22:219
  25. As cardiovascular disease (CVD) is a leading cause of death for patients with diabetes mellitus (DM), we aimed to find important factors that predict cardiovascular (CV) risk using a machine learning (ML) appr...

    Authors: Hanna Kwiendacz, Agata M. Wijata, Jakub Nalepa, Julia Piaśnik, Justyna Kulpa, Mikołaj Herba, Sylwia Boczek, Kamil Kegler, Mirela Hendel, Krzysztof Irlik, Janusz Gumprecht, Gregory Y. H. Lip and Katarzyna Nabrdalik
    Citation: Cardiovascular Diabetology 2023 22:218
  26. Agonism at the receptor for the glucose-dependent insulinotropic polypeptide (GIPR) is a key component of the novel unimolecular GIPR:GLP-1R co-agonists, which are among the most promising drugs in clinical de...

    Authors: Stephan Sachs, Anna Götz, Brian Finan, Annette Feuchtinger, Richard D. DiMarchi, Yvonne Döring, Christian Weber, Matthias H. Tschöp, Timo D. Müller and Susanna M. Hofmann
    Citation: Cardiovascular Diabetology 2023 22:217
  27. Myocardial microvascular injury is the key event in early diabetic heart disease. The injury of myocardial microvascular endothelial cells (CMECs) is the main cause and trigger of myocardial microvascular dise...

    Authors: Xide Shi, Chao Liu, Jiangwei Chen, Shiqiang Zhou, Yajuan Li, Xingcheng Zhao, Jinliang Xing, Junhui Xue, Fengzhou Liu and Fei Li
    Citation: Cardiovascular Diabetology 2023 22:216
  28. In AFFIRM-AHF, treatment of iron deficiency with intravenous ferric carboxymaltose (FCM) reduced the risk of heart failure (HF) hospitalization and improved quality of life (QoL) vs placebo in patients stabili...

    Authors: Giuseppe Rosano, Piotr Ponikowski, Cristiana Vitale, Stefan D. Anker, Javed Butler, Vincent Fabien, Gerasimos Filippatos, Bridget-Anne Kirwan, Iain C. Macdougall, Marco Metra, Frank Ruschitzka, Vasuki Kumpeson, Udo-Michael Goehring, Peter van der Meer and Ewa A. Jankowska
    Citation: Cardiovascular Diabetology 2023 22:215
  29. Cardiac steatosis is an early yet overlooked feature of diabetic cardiomyopathy. There is no available therapy to treat this condition. Tyrosine kinase inhibitors (TKIs) are used as first or second-line therap...

    Authors: Yue Gu, Elisa Avolio, Valeria V Alvino, Anita C Thomas, Andrew Herman, Poppy J Miller, Niall Sullivan, Ashton Faulkner and Paolo Madeddu
    Citation: Cardiovascular Diabetology 2023 22:214
  30. The accumulation of advanced glycation end products (AGEs) is associated with cardiovascular events in patients with cardiovascular disease (CVD). However, the relationship between the AGEs measured by an AGEs...

    Authors: Tomoya Hirai, Kazuhiro Fujiyoshi, Satoru Yamada, Takuya Matsumoto, Junko Kikuchi, Kohki Ishida, Miwa Ishida, Kyo Shigeta and Taiki Tojo
    Citation: Cardiovascular Diabetology 2023 22:213
  31. While a low-carbohydrate diet (LCD) reduces HbA1c in patients with type 2 diabetes (T2D), the associated high intake of fat may adversely affect cardiovascular risk factors. To address this, we examined the ef...

    Authors: Eva M. Gram-Kampmann, Thomas B. Olesen, Camilla D. Hansen, Mie B. Hugger, Jane M. Jensen, Aase Handberg, Henning Beck-Nielsen, Aleksander Krag, Michael H. Olsen and Kurt Højlund
    Citation: Cardiovascular Diabetology 2023 22:212
  32. Heterogeneous metabolic clusters have been identified in diabetic and prediabetic states. It is not known whether such pathophysiologic clusters impact survival in at-risk persons being evaluated for coronary ...

    Authors: Katsiaryna Prystupa, Graciela E. Delgado, Angela P. Moissl, Marcus E. Kleber, Andreas L. Birkenfeld, Martin Heni, Andreas Fritsche, Winfried März and Robert Wagner
    Citation: Cardiovascular Diabetology 2023 22:211
  33. Atherogenic index of plasma (AIP) has been confirmed as a novel marker for myocardial infarction (MI), but few evidence on the long-term AIP and MI risk in general populations. We thus aimed to evaluate the re...

    Authors: Yijun Zhang, Shuohua Chen, Xue Tian, Penglian Wang, Qin Xu, Xue Xia, Xiaoli Zhang, Jing Li, Fen Liu, Shouling Wu and Anxin Wang
    Citation: Cardiovascular Diabetology 2023 22:210
  34. The concept of early vascular aging (EVA) represents a potentially beneficial model for future research into the pathophysiological mechanisms underlying the early manifestations of cardiovascular disease. For...

    Authors: Alicia Saz-Lara, Iván Cavero-Redondo, Carlos Pascual-Morena, Irene Martínez-García, Eva Rodríguez-Gutiérrez, Maribel Lucerón-Lucas-Torres, Bruno Bizzozero-Peroni, Nerea Moreno-Herráiz and Arturo Martínez-Rodrigo
    Citation: Cardiovascular Diabetology 2023 22:209
  35. Empagliflozin reduces the risk of cardiovascular disease (CVD) in patients with type 2 diabetes (T2DM) and high cardiovascular risk via mechanisms which have not been fully explained. The mechanisms of such be...

    Authors: Elena Fortin, Magnus Lundin, Linda Mellbin, Anna Norhammar, Per Näsman, Stina Smetana, Peder Sörensson, Ele Ferrannini, Lars Rydén and Giulia Ferrannini
    Citation: Cardiovascular Diabetology 2023 22:208
  36. Emerging evidence suggests that remnant cholesterol (RC) is strongly associated with an increased incidence of cardiometabolic diseases (CMD). However, the causality have not been confirmed. We aimed to evalua...

    Authors: Baoyi Guan, Anlu Wang and Hao Xu
    Citation: Cardiovascular Diabetology 2023 22:207
  37. The differences in fat deposition sites exhibit varying degrees of systemic inflammatory responses and organ damage, especially in obese individuals with excessive visceral fat. Visceral fat, which is closely ...

    Authors: Jinquan Bai, Chao Gao, Xiaolu Li, Hong Pan, Shuting Wang, Zhenzhou Shi and Tong Zhang
    Citation: Cardiovascular Diabetology 2023 22:206
  38. The atherogenic index of plasma (AIP) can reflect the burden of atherosclerosis. Hyperglycemia is one of the leading causes of atherosclerosis. However, the relationship between AIP and prediabetes is rarely s...

    Authors: Xiaodan Zheng, Xin Zhang, Yong Han, Haofei Hu and Changchun Cao
    Citation: Cardiovascular Diabetology 2023 22:205
  39. We assessed whether hepatic steatosis with or without significant fibrosis (determined by validated non-invasive biomarkers) is associated with an increased 10-year estimated risk for cardiovascular disease (C...

    Authors: Alessandro Mantovani, Mario Luca Morieri, Luisa Palmisano, Maria Masulli, Efisio Cossu, Marco Giorgio Baroni, Katia Bonomo, Flavia Agata Cimini, Gisella Cavallo, Raffaella Buzzetti, Carmen Mignogna, Frida Leonetti, Simonetta Bacci, Roberto Trevisan, Riccardo Maria Pollis, Raffaella Aldigeri…
    Citation: Cardiovascular Diabetology 2023 22:204
  40. Albuminuria has been suggested as an atherosclerotic risk factor among the general population. However, whether this association will be amplified in patients with coronary artery disease (CAD) is unknown. It ...

    Authors: Xueqin Lin, Wei Song, Yang Zhou, Yuwei Gao, Yani Wang, Yun Wang, Yuchen Liu, Lin Deng, Yin Liao, Bo Wu, Shiqun Chen, Liling Chen and Yong Fang
    Citation: Cardiovascular Diabetology 2023 22:203
  41. This study aimed to investigate the effect of glycemic variability (GV), determined using a continuous glucose monitoring system (CGMS), on left ventricular reverse remodeling (LVRR) after ST-segment elevation...

    Authors: Yohei Hanajima, Noriaki Iwahashi, Jin Kirigaya, Mutsuo Horii, Yugo Minamimoto, Masaomi Gohbara, Takeru Abe, Kozo Okada, Yasushi Matsuzawa, Masami Kosuge, Toshiaki Ebina and Kiyoshi Hibi
    Citation: Cardiovascular Diabetology 2023 22:202
  42. Insulin is commonly used in type 2 diabetes mellitus (T2DM) to achieve glycemic control. However, recent evidence showed that insulin use is associated with poor outcomes in the context of heart failure (HF). ...

    Authors: Ke Shi, Ge Zhang, Hang Fu, Shan Huang, Hua-Yan Xu, Yue Gao, Rui Shi, Wei-Feng Yan, Wen-Lei Qian, Yuan Li, Ying-Kun Guo and Zhi-Gang Yang
    Citation: Cardiovascular Diabetology 2023 22:201
  43. Various predictive models have been developed for predicting the incidence of coronary heart disease (CHD), but none of them has had optimal predictive value. Although these models consider diabetes as an impo...

    Authors: Seyed Reza Mirjalili, Sepideh Soltani, Zahra Heidari Meybodi, Pedro Marques-Vidal, Alexander Kraemer and Mohammadtaghi Sarebanhassanabadi
    Citation: Cardiovascular Diabetology 2023 22:200
  44. We aimed to identify a lipidic profile associated with type 2 diabetes mellitus (T2DM) development in coronary heart disease (CHD) patients, to provide a new, highly sensitive model which could be used in clin...

    Authors: Alejandro Villasanta-Gonzalez, Marina Mora-Ortiz, Juan F. Alcala-Diaz, Lorenzo Rivas-Garcia, Jose D. Torres-Peña, Asuncion Lopez-Bascon, Monica Calderon-Santiago, Antonio P. Arenas-Larriva, Feliciano Priego‑Capote, Maria M. Malagon, Fabian Eichelmann, Pablo Perez-Martinez, Javier Delgado-Lista, Matthias B. Schulze, Antonio Camargo and Jose Lopez-Miranda
    Citation: Cardiovascular Diabetology 2023 22:199
  45. Early identification of populations at high cardiovascular disease (CVD) risk and improvement of risk factors can significantly decrease the probability of CVD development and improve outcomes. Insulin resista...

    Authors: Xiao-ling Cai, Yi-fei Xiang, Xiao-fang Chen, Xue-qin Lin, Bi-ting Lin, Geng-yu Zhou, Lin Yu, Yan-song Guo and Kai-yang Lin
    Citation: Cardiovascular Diabetology 2023 22:198
  46. Patients with heart failure have increased cardiac filling pressures, circulating natriuretic peptides, and physical signs of fluid retention, which are related to sodium retention by the kidneys and are allev...

    Authors: Milton Packer
    Citation: Cardiovascular Diabetology 2023 22:197

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Annual Journal Metrics

  • 2022 Citation Impact
    9.3 - 2-year Impact Factor
    9.6 - 5-year Impact Factor
    2.054 - SNIP (Source Normalized Impact per Paper)
    2.361 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    56 days submission to accept (Median)

    2023 Usage 
    2,523,778 downloads
    3,115 Altmetric mentions